Theravance Biopharma (NASDAQ:TBPH) Stock Unloaded Rep. George Whitesides

Representative George Whitesides (D-California) recently sold shares of Theravance Biopharma, Inc. NASDAQ: TBPH. In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Theravance Biopharma stock on March 24th. The trade occurred in the Representative's "GEORGE WHITESIDES INDIVIDUAL" account.

Representative George Whitesides also recently made the following trade(s):

• Sold $100,001 - $250,000 in shares of Netflix NASDAQ: NFLX on 3/27/2025.
• Sold $250,001 - $500,000 in shares of Innoviva NASDAQ: INVA on 3/25/2025.
• Sold $100,001 - $250,000 in shares of Linde NASDAQ: LIN on 3/24/2025.
• Sold $100,001 - $250,000 in shares of Procter & Gamble NYSE: PG on 3/24/2025.
• Sold $1,001 - $15,000 in shares of Sandoz Group OTCMKTS: SDZNY on 3/24/2025.
• Sold $15,001 - $50,000 in shares of American Electric Power NASDAQ: AEP on 3/24/2025.
• Sold $50,001 - $100,000 in shares of Medtronic NYSE: MDT on 3/24/2025.
• Sold $100,001 - $250,000 in shares of McDonald's NYSE: MCD on 3/24/2025.
• Sold $15,001 - $50,000 in shares of Bank of America NYSE: BAC on 3/24/2025.
• Sold $15,001 - $50,000 in shares of Diageo NYSE: DEO on 3/24/2025.

Theravance Biopharma Price Performance

NASDAQ TBPH traded down $0.25 on Tuesday, hitting $9.50. 223,966 shares of the stock were exchanged, compared to its average volume of 280,456. The business's fifty day moving average is $9.10 and its 200 day moving average is $9.22. Theravance Biopharma, Inc. has a 52 week low of $7.44 and a 52 week high of $10.90. The company has a market capitalization of $475.01 million, a PE ratio of -9.41 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). The firm had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TBPH. Aquatic Capital Management LLC bought a new stake in shares of Theravance Biopharma during the fourth quarter worth approximately $25,000. GAMMA Investing LLC lifted its holdings in Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 3,281 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Theravance Biopharma in the 4th quarter valued at $69,000. Teacher Retirement System of Texas acquired a new position in Theravance Biopharma in the 4th quarter valued at $103,000. Finally, ClearAlpha Technologies LP bought a new position in Theravance Biopharma during the 4th quarter worth $109,000. Institutional investors and hedge funds own 99.10% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $11.33.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This trade represents a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.90% of the company's stock.

About Representative Whitesides

George Whitesides (Democratic Party) is a member of the U.S. House, representing California's 27th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Whitesides (Democratic Party) ran for election to the U.S. House to represent California's 27th Congressional District. He won in the general election on November 5, 2024. George Whitesides earned a bachelor's degree in public and international affairs from Princeton University in 1996 and a master's degree in remote sensing and GIS from the University of Cambridge in 2000. His career experience includes working as the chief of staff for NASA during the administration of President Barack Obama (D) and the CEO of human spaceflight company Virgin Galactic. Whitesides co-founded Megafire Action, an organization dedicated to responding to wildfires. Whitesides co-chaired the Antelope Valley Covid-19 Task Force and joined the Antelope Valley Economic Development and Growth Enterprise (AV EDGE) as a board member.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.